Table 4.

Areas of Opportunity for Oral Ultra Long-acting Dosage Forms

Existing Non-Proprietary Agents	Provide patient-centric options for superior pharmacology and adherence for existing small molecule drugs. Especially for medications with: short half-lives narrow GI absorption windows narrow therapeutic indices and diseases where: adherence is closely related to product performance, or where dose reduction/ reduced dosing frequency would improve patient outcomes significantly
Combination Products	Where multiple oral drugs can be combined in a long-acting formulation: medications for common comorbid conditions patients with diseases requiring polypharmacy
Targeted or Non-systemic Delivery	Conditions where targeted GI delivery improves bioavailability or avoids systemic drug exposure: local GI Delivery with controlled targeting to upper and/or lower portions of the GI tract enhanced safety profile by providing locally acting and/or rapidly metabolized drugs where systemic exposure is not required
Point of Care Administration	Regimens that achieve a full treatment course in a single, long-acting dose: applications in emergency medicine /urgent care short course treatments applications for transition in care (discharge medications) rural or tropical medicine (eg. mass drug administration campaigns) direct observed therapies
New Chemical Entities	Development of new therapeutic agents with low dose (high potency), where: long acting delivery may be advantageous where any of the above considerations may also be helpful to a patient population